Xingping Aripiprazole Oral Soluble Film

1. Indications and Usage
Schizophrenia: Indicated for the treatment of schizophrenia in adults and adolescents (13 to 17 years of age).
Bipolar I Disorder: Indicated for the acute treatment of manic or mixed episodes associated with Bipolar I Disorder in adults and pediatric patients (10 to 17 years of age).
Autism: Indicated for the treatment of irritability associated with autistic disorder in pediatric patients (6 to 17 years of age).
2. Dosage and Administration
Administration Method: Place the film on the tongue where it will rapidly disintegrate without the need for water.
Schizophrenia: The recommended starting dose for adults and adolescents is 10 mg or 15 mg once daily. The maximum recommended dose is 30 mg/day.
Bipolar I Disorder: The recommended starting dose for adults is 15 mg once daily (monotherapy) or 5 mg once daily (adjunctive therapy). For pediatric patients, the starting dose is 2 mg once daily.
Irritability with Autistic Disorder: The recommended starting dose is 2 mg once daily, with a maximum recommended dose of 15 mg/day.
Dose Adjustments: Adjustments may be necessary when co-administered with strong CYP3A4 or CYP2D6 inhibitors/inducers.
3. Mechanism of Action
Receptor Modulation: Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors.
Neurotransmitter Stabilization: This unique mechanism stabilizes dopaminergic and serotonergic neurotransmission, effectively treating positive symptoms (e.g., hallucinations, delusions) while maintaining cognitive and negative symptom function.
4. Safety and Warnings
Elderly Patients with Dementia-Related Psychosis: Antipsychotics increase the risk of death in elderly patients with dementia-related psychosis.
Suicidal Thoughts and Behaviors: Monitoring for clinical worsening or emergence of suicidality is required, particularly in pediatric and young adult populations.
Metabolic Changes: Antipsychotics can cause hyperglycemia, diabetes, dyslipidemia, and weight gain.
Tardive Dyskinesia and NMS: Risk of irreversible movement disorders and Neuroleptic Malignant Syndrome (NMS), a potentially fatal reaction.
Orthostatic Hypotension: May cause dizziness and syncope due to alpha-1 adrenergic receptor antagonism.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Common adverse reactions include nausea, vomiting, constipation, headache, dizziness, akathisia (restlessness), extrapyramidal symptoms, and anxiety.
Clinical Research: Clinical trials have demonstrated the efficacy and rapid onset of action of oral soluble films in controlling acute psychiatric symptoms with improved patient compliance compared to traditional tablet formulations.
6. Drug Interactions
CYP3A4 and CYP2D6 Inhibitors: Drugs like ketoconazole or fluoxetine can increase aripiprazole plasma concentrations; dose reduction is often required.
CYP3A4 Inducers: Drugs like carbamazepine can decrease aripiprazole plasma concentrations; dose increase may be necessary.
Antihypertensives: May potentiate orthostatic hypotension.
Other CNS Agents: Concomitant use with alcohol or other CNS depressants should be monitored.
7. Pharmaceutical Information
Composition: The active ingredient is aripiprazole. The matrix typically contains hydroxypropyl cellulose, sucralose, and flavoring agents to enable rapid dissolution.
Appearance: Thin, flexible film available in various strengths, packed in individual blister packs.
Storage: Store at controlled room temperature and protect from moisture.